Principal Findings:

The primary efficacy outcome, major adverse cardiovascular events (vascular death, myocardial infarction, or stroke/transient ischemic attack), occurred in 8.9% of the omega-3 group compared with 9.2% of the placebo group (p = 0.55).

There was no treatment interaction according to different categories of baseline risk.

Interpretation:

Among diabetic patients with no known CVD, omega-3 fatty acid supplementation was not beneficial. Omega-3 fatty acids failed to reduce the incidence of major adverse cardiovascular events compared with placebo. Omega-3 fatty acid also failed to reduce the incidence of major adverse cardiovascular events or revascularization, atrial fibrillation, or ventricular arrhythmia compared with placebo. Routine dietary supplementation of omega-3 fatty acids is not recommended.

References:

Presented by Dr. Sarah Parish at the European Society of Cardiology Congress, Paris, France, August 31, 2019.